Acceleron Pharma competitors

Acceleron Pharma's competitors include Bio-Path Holdings, Roche, Allergan and Novartis
Add company...
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Bio-Path Holdings
Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.
Roche
Roche Holding is a diagnostics and pharmaceutical company.
Allergan
Allergan is a global pharmaceutical company.
Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies.
Founding Date
Founding Date
2003
Founding Date
2007
Founding Date
1896
Founding Date
1948
Founding Date
1996
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Locations
Bellaire, US HQ
Locations
Basel, CH HQ
South San Francisco, US
Locations
Dublin, IE HQ
Parsippany Troy Hills, US
Locations
Basel, CH HQ
Beijing, CN
Wehr, DE
Tokyo, JP
New York, US
East Hanover, US
Employees
Employees
121
Employees
12
Employees
93,734
Employees
16,70046% decrease
Employees
126,0004% increase
Valuation ($)
Valuation ($)
2.1 b
Valuation ($)
18.3 m
Valuation ($)
N/A
Valuation ($)
59.6 b
Valuation ($)
175.5 b
Facebook likes
Facebook likes
N/A
Facebook likes
14
Facebook likes
80.2 k
Facebook likes
219
Facebook likes
304.3 k
Twitter followers
Twitter followers
499
Twitter followers
N/A
Twitter followers
177.2 k
Twitter followers
23 k
Twitter followers
234.4 k

Financial

Revenue (est.)
Revenue (est.)
$13.5m (FY, 2017)
Revenue (est.)
$13k (FY, 2016)
Revenue (est.)
CHF48.1b (FY, 2015)
Revenue (est.)
N/A
Revenue (est.)
$48.5b (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
CHF15.5b (FY, 2015)
Cost of goods
N/A
Cost of goods
$17.5b (FY, 2016)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
CHF32.7b (FY, 2015)
Gross profit
N/A
Gross profit
$31b (FY, 2016)
Net income
Net income
($108.5m) (FY, 2017)
Net income
($6.8m) (FY, 2016)
Net income
CHF9.1b (FY, 2015)
Net income
N/A
Net income
$6.7b (FY, 2016)

Operating

Major Approvals (US, EU, JP)
Major Approvals (US, EU, JP)
N/A
Major Approvals (US, EU, JP)
N/A
Major Approvals (US, EU, JP)
12 (Y, 2016)
Major Approvals (US, EU, JP)
N/A
Major Approvals (US, EU, JP)
16 (Y, 2016)
Phase III Trials Products
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
29 (Y, 2016)
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
5 (Y, 2016)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
5 (Y, 2016)

Funding

Total funding raised
Total funding raised
$ 122.8m
Total funding raised
$ 2.3m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 6.5m
For sources of this data, please see the company profileDownload Excel

View company profiles

Bio-Path Holdings
HQ
Bellaire, US
Employees
12

Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.

View company
Roche
HQ
Basel, CH
Employees
93,734

Roche Holding is a diagnostics and pharmaceutical company.

View company
Allergan
HQ
Dublin, IE
Employees
16,700↓ 46% decrease

Allergan is a global pharmaceutical company.

View company
Novartis
HQ
Basel, CH
Employees
126,000↑ 4% increase

Novartis provides healthcare solutions that address the evolving needs of patients and societies.

View company